10-K Filing

INSIGHT MOLECULAR DIAGNOSTICS INC. CIK: 1642380 FY 2022

Filing Information

Form Type	10-K
Accession Number	`0001493152-23-012005`
Period End Date	20221231
Filing Date	20230412
Fiscal Year	2022
Fiscal Period	FY
XBRL Instance	form10-k_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 87 Income Statement 56 Cash Flow Statement 94 Stockholders Equity 23 Comprehensive Income 6

Balance Sheet 87 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$32.95M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$19.99M	USD	Point-in-time
Accounts receivable, net of allowance of $154 and $-, respectively	`AccountsReceivableNetCurrent`	$2.01M	USD	Point-in-time
Accounts receivable, net of allowance of $154 and $-, respectively	`AccountsReceivableNetCurrent`	$1.44M	USD	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$904.00K	USD	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$433.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$901.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$977.00K	USD	Point-in-time
Accounts Receivable, Allowance for Credit Loss	`AllowanceForDoubtfulAccountsReceivable`	$154.00K	USD	Point-in-time
Current assets of discontinuing operations	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$2.95M	USD	Point-in-time
Current assets of discontinuing operations	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$2.12M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$39.14M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$25.54M	USD	Point-in-time
Right-of-use and financing lease assets, net	`FinanceLeaseRightOfUseAsset`	$2.09M	USD	Point-in-time
Right-of-use and financing lease assets, net	`FinanceLeaseRightOfUseAsset`	$2.78M	USD	Point-in-time
Machinery and equipment, net, and construction in progress	`MachineryAndEquipmentNetAndConstructionInProgress`	$8.76M	USD	Point-in-time
Machinery and equipment, net, and construction in progress	`MachineryAndEquipmentNetAndConstructionInProgress`	$5.59M	USD	Point-in-time
Goodwill	`Goodwill`	-	USD	Point-in-time
Goodwill	`Goodwill`	$9.49M	USD	Point-in-time
Preferred stock no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Preferred stock no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Goodwill	`Goodwill`	$18.68M	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$61.63M	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$61.72M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$1.70M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$1.70M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$264.00K	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$371.00K	USD	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Other noncurrent assets of discontinuing operations	`DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent`	$29.68M	USD	Point-in-time
Other noncurrent assets of discontinuing operations	`DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent`	-	USD	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	230.00M	shares	Point-in-time
TOTAL ASSETS	`Assets`	$159.56M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	230.00M	shares	Point-in-time
TOTAL ASSETS	`Assets`	$100.09M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	118.64M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	92.23M	shares	Point-in-time
Common stock, shares, outstanding	`CommonStockSharesOutstanding`	118.64M	shares	Point-in-time
Common stock, shares, outstanding	`CommonStockSharesOutstanding`	92.23M	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.25M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.81M	USD	Point-in-time
Accrued compensation	`AccruedLiabilitiesCurrent`	$2.83M	USD	Point-in-time
Accrued compensation	`AccruedLiabilitiesCurrent`	$1.77M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$3.84M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$2.08M	USD	Point-in-time
Accrued severance from acquisition	`AccruedSeveranceFromAcquisitionCurrent`	$2.31M	USD	Point-in-time
Accrued severance from acquisition	`AccruedSeveranceFromAcquisitionCurrent`	$2.35M	USD	Point-in-time
Accrued liabilities from acquisition	`BusinessCombinationContingentConsiderationLiabilityCurrent`	$109.00K	USD	Point-in-time
Accrued liabilities from acquisition	`BusinessCombinationContingentConsiderationLiabilityCurrent`	$1.39M	USD	Point-in-time
Loans payable, net of deferred financing costs	`LoansPayableCurrent`	$1.31M	USD	Point-in-time
Loans payable, net of deferred financing costs	`LoansPayableCurrent`	-	USD	Point-in-time
Right-of-use and financing lease liabilities, current	`OperatingLeaseAndFinancingLeaseLiabilitiesCurrent`	$819.00K	USD	Point-in-time
Right-of-use and financing lease liabilities, current	`OperatingLeaseAndFinancingLeaseLiabilitiesCurrent`	$815.00K	USD	Point-in-time
Current liabilities of discontinuing operations	`LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$2.00M	USD	Point-in-time
Current liabilities of discontinuing operations	`LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$1.53M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$14.12M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$12.11M	USD	Point-in-time
Right-of-use and financing lease liabilities, noncurrent	`OperatingLeaseLiabilitiesAndFinancingLeaseLiabilitiesNonCurrent`	$3.54M	USD	Point-in-time
Right-of-use and financing lease liabilities, noncurrent	`OperatingLeaseLiabilitiesAndFinancingLeaseLiabilitiesNonCurrent`	$2.73M	USD	Point-in-time
Contingent consideration liabilities	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$76.68M	USD	Point-in-time
Contingent consideration liabilities	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$45.66M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$94.35M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$60.50M	USD	Point-in-time
COMMITMENTS AND CONTINGENCIES	`CommitmentsAndContingencies`	-	USD	Point-in-time
COMMITMENTS AND CONTINGENCIES	`CommitmentsAndContingencies`	-	USD	Point-in-time
Series A Redeemable Convertible Preferred Stock, no par value; stated value $1,000 per share; 6 shares and - shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively; aggregate liquidation preference of $6,091 and $- as of December 31, 2022 and December 31, 2021, respectively	`TemporaryEquityCarryingAmountAttributableToParent`	-	USD	Point-in-time
Series A Redeemable Convertible Preferred Stock, no par value; stated value $1,000 per share; 6 shares and - shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively; aggregate liquidation preference of $6,091 and $- as of December 31, 2022 and December 31, 2021, respectively	`TemporaryEquityCarryingAmountAttributableToParent`	$5.30M	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, no par value, 230,000 shares authorized; 118,644 and 92,232 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively	`CommonStockValue`	$294.93M	USD	Point-in-time
Common stock, no par value, 230,000 shares authorized; 118,644 and 92,232 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively	`CommonStockValue`	$252.95M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$39.00K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$37.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-187.77M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-260.68M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$34.29M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$65.22M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$33.48M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$159.56M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$100.09M	USD	Point-in-time

Income Statement 56 line items

Line Item	Tag	Value	Unit	Period
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$958.00K	USD	Annual
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$2.20M	USD	Annual
Cost of revenues	`CostOfRevenue`	$880.00K	USD	Annual
Cost of revenues	`CostOfRevenue`	$697.00K	USD	Annual
Cost of revenues amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	$81.00K	USD	Annual
Cost of revenues amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	$96.00K	USD	Annual
Gross margin	`GrossProfit`	$-18.00K	USD	Annual
Gross margin	`GrossProfit`	$1.42M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$5.04M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$7.30M	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$1.13M	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$552.00K	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$22.29M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$21.88M	USD	Annual
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$27.27M	USD	Annual
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-31.02M	USD	Annual
Loss from goodwill impairment	`GoodwillImpairmentLoss`	-	USD	Annual
Loss from goodwill impairment	`GoodwillImpairmentLoss`	$18.68M	USD	Annual
Total operating expenses	`OperatingExpenses`	$17.98M	USD	Annual
Total operating expenses	`OperatingExpenses`	$55.15M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-18.00M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-53.73M	USD	Annual
Interest expense, net	`InterestIncomeExpenseNet`	$-209.00K	USD	Annual
Interest expense, net	`InterestIncomeExpenseNet`	$-77.00K	USD	Annual
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$229.00K	USD	Annual
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-471.00K	USD	Annual
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-270.00K	USD	Annual
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	-	USD	Annual
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	$1.14M	USD	Annual
Other expenses, net	`OtherNonoperatingIncomeExpense`	$-67.00K	USD	Annual
Other expenses, net	`OtherNonoperatingIncomeExpense`	$-37.00K	USD	Annual
Total other income (expenses), net	`NonoperatingIncomeExpense`	$854.00K	USD	Annual
Total other income (expenses), net	`NonoperatingIncomeExpense`	$-615.00K	USD	Annual
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-52.87M	USD	Annual
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-18.61M	USD	Annual
Income tax benefit	`IncomeTaxExpenseBenefit`	$-9.26M	USD	Annual
Income tax benefit	`IncomeTaxExpenseBenefit`	-	USD	Annual
Loss from continuing operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$-18.61M	USD	Annual
Loss from continuing operations	`IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest`	$-43.61M	USD	Annual
Loss from discontinuing operations	`IncomeLossFromDiscontinuedOperationsNetOfTax`	$-54.29M	USD	Annual
Loss from discontinuing operations	`IncomeLossFromDiscontinuedOperationsNetOfTax`	$-20.49M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-64.10M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-72.90M	USD	Annual
Accretion of Series A redeemable convertible preferred stock	`AccretionOfSeriesRedeemableConvertiblePreferredStock`	-	USD	Annual
Accretion of Series A redeemable convertible preferred stock	`AccretionOfSeriesRedeemableConvertiblePreferredStock`	$520.00K	USD	Annual
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS: BASIC AND DILUTED	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-64.10M	USD	Annual
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS: BASIC AND DILUTED	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-73.42M	USD	Annual
Net loss per share from continuing operations, basic and diluted	`IncomeLossFromContinuingOperationsPerBasicShare`	$-0.49	USD	Annual
Net loss per share from continuing operations, basic and diluted	`IncomeLossFromContinuingOperationsPerBasicShare`	$-0.17	USD	Annual
Net loss per share from discontinuing operations, basic and diluted	`IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare`	$-0.49	USD	Annual
Net loss per share from discontinuing operations, basic and diluted	`IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare`	$-0.23	USD	Annual
Net loss per share: basic and diluted	`EarningsPerShareBasic`	$-0.66	USD	Annual
Net loss per share: basic and diluted	`EarningsPerShareBasic`	$-0.72	USD	Annual
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfSharesOutstandingBasic`	110,800.00	shares	Annual
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfSharesOutstandingBasic`	88,920.00	shares	Annual

Cash Flow Statement 94 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-64.10M	USD	Annual
Net loss	`NetIncomeLoss`	$-72.90M	USD	Annual
Depreciation expense	`Depreciation`	$1.53M	USD	Annual
Depreciation expense	`Depreciation`	$844.00K	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$3.69M	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$3.36M	USD	Annual
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-270.00K	USD	Annual
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	-	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$10.04M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$6.84M	USD	Annual
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$229.00K	USD	Annual
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-471.00K	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$12.00K	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$56.00K	USD	Annual
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$27.27M	USD	Annual
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-31.02M	USD	Annual
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-9.26M	USD	Annual
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	-	USD	Annual
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	$1.14M	USD	Annual
Loss from goodwill impairment	`GoodwillImpairmentLoss`	-	USD	Annual
Loss from goodwill impairment	`GoodwillImpairmentLoss`	$18.68M	USD	Annual
Impairment loss from held for sale assets	`GainLossOnSaleOfLeasedAssetsNetOperatingLeases`	-	USD	Annual
Impairment loss from held for sale assets	`GainLossOnSaleOfLeasedAssetsNetOperatingLeases`	$-25.87M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$1.23M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$575.00K	USD	Annual
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-116.00K	USD	Annual
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$147.00K	USD	Annual
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$231.00K	USD	Annual
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-227.00K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$297.00K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-1.35M	USD	Annual
Accrued severance and liabilities from Chronix Biomedical acquisition	`AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition`	$1.32M	USD	Annual
Accrued severance and liabilities from Chronix Biomedical acquisition	`AccruedSeveranceAndLiabilitiesFromChronixBiomedicalAcquisition`	$-2.35M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-45.57M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-35.94M	USD	Annual
Acquisition of Insight Genetics, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$607.00K	USD	Annual
Acquisition of Insight Genetics, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	-	USD	Annual
Acquisition of Razor Genomics asset, net of cash acquired	`AcquisitionOfRazorGenomicsAssetNetOfCashAcquired`	$6.65M	USD	Annual
Acquisition of Razor Genomics asset, net of cash acquired	`AcquisitionOfRazorGenomicsAssetNetOfCashAcquired`	-	USD	Annual
Acquisition of Chronix Biomedical, net of cash acquired	`AcquisitionOfChronixBiomedicalNetOfCashAcquired`	$4.46M	USD	Annual
Acquisition of Chronix Biomedical, net of cash acquired	`AcquisitionOfChronixBiomedicalNetOfCashAcquired`	-	USD	Annual
Construction in progress and purchases of equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$4.34M	USD	Annual
Construction in progress and purchases of equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$2.25M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-13.96M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-4.34M	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	-	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$2.58M	USD	Annual
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	$32.81M	USD	Annual
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	$65.26M	USD	Annual
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	$389.00K	USD	Annual
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	$2.67M	USD	Annual
Proceeds from sale of redeemable convertible Series A preferred shares	`ProceedsFromSaleOfRedeemableConvertibleSeriesPreferredShares`	$4.88M	USD	Annual
Proceeds from sale of redeemable convertible Series A preferred shares	`ProceedsFromSaleOfRedeemableConvertibleSeriesPreferredShares`	-	USD	Annual
Financing costs to issue redeemable convertible Series A preferred shares	`FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares`	$93.00K	USD	Annual
Financing costs to issue redeemable convertible Series A preferred shares	`FinancingCostsToIssueRedeemableConvertibleSeriesPreferredShares`	-	USD	Annual
Proceeds from sale of common shares under at-the-market transactions	`ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions`	$12.72M	USD	Annual
Proceeds from sale of common shares under at-the-market transactions	`ProceedsFromSaleOfCommonSharesUnderAtthemarketTransactions`	$31.00K	USD	Annual
Financing costs for at-the-market sales	`PaymentForFinancingCostsForAtthemarketSales`	$390.00K	USD	Annual
Financing costs for at-the-market sales	`PaymentForFinancingCostsForAtthemarketSales`	$1.00K	USD	Annual
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	Annual
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$2.63M	USD	Annual
Common shares received and retired for employee taxes paid	`CommonSharesReceivedAndRetiredForEmployeeTaxesPaid`	$239.00K	USD	Annual
Common shares received and retired for employee taxes paid	`CommonSharesReceivedAndRetiredForEmployeeTaxesPaid`	-	USD	Annual
Repayment of loan payable	`RepaymentsOfDebt`	$1.50M	USD	Annual
Repayment of loan payable	`RepaymentsOfDebt`	$1.32M	USD	Annual
Repayment of financing lease obligations	`RepaymentOfFinancingLeaseObligations`	$34.00K	USD	Annual
Repayment of financing lease obligations	`RepaymentOfFinancingLeaseObligations`	$104.00K	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$78.36M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$35.81M	USD	Annual
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$28.46M	USD	Annual
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-14.10M	USD	Annual
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$37.30M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.84M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$23.20M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$37.30M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.84M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$23.20M	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	$114.00K	USD	Annual
Cash paid for interest	`InterestPaidNet`	$24.00K	USD	Annual
Common stock issued for acquisition of Razor Genomics asset	`StockIssued1`	$5.76M	USD	Annual
Common stock issued for acquisition of Razor Genomics asset	`StockIssued1`	-	USD	Annual
Deferred tax liability generated from the acquisition of Razor Genomics asset	`DeferredTaxLiabilityGeneratedFromAcquisitionOfRazorGenomicsAsset`	$7.08M	USD	Annual
Deferred tax liability generated from the acquisition of Razor Genomics asset	`DeferredTaxLiabilityGeneratedFromAcquisitionOfRazorGenomicsAsset`	-	USD	Annual
Common stock issued for acquisition of Chronix Biomedical	`CommonStockIssuedForAcquisitionOfChronixBiomedical`	$3.30M	USD	Annual
Common stock issued for acquisition of Chronix Biomedical	`CommonStockIssuedForAcquisitionOfChronixBiomedical`	-	USD	Annual
Deferred tax liability generated from the acquisition of Chronix	`DeferredTaxLiabilityGeneratedFromAcquisitionOfChronix`	$2.18M	USD	Annual
Deferred tax liability generated from the acquisition of Chronix	`DeferredTaxLiabilityGeneratedFromAcquisitionOfChronix`	-	USD	Annual
Initial fair value of contingent consideration at acquisition date	`InitialFairValueOfContingentConsiderationAtAcquisitionDate`	-	USD	Annual
Initial fair value of contingent consideration at acquisition date	`InitialFairValueOfContingentConsiderationAtAcquisitionDate`	$42.30M	USD	Annual
Assumed liability from Chronix Acquisition	`AssumedLiabilityFromChronixAcquisition`	$3.35M	USD	Annual
Assumed liability from Chronix Acquisition	`AssumedLiabilityFromChronixAcquisition`	-	USD	Annual
Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability	`ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability`	$1.08M	USD	Annual
Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability	`ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability`	$323.00K	USD	Annual

Stockholders Equity 23 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquity`	$34.29M	USD	Point-in-time
Balance	`StockholdersEquity`	$65.22M	USD	Point-in-time
Balance	`StockholdersEquity`	$33.48M	USD	Point-in-time
Net Loss	`NetIncomeLoss`	$-64.10M	USD	Annual
Net Loss	`NetIncomeLoss`	$-72.90M	USD	Annual
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$37.00K	USD	Annual
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$2.00K	USD	Annual
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$6.84M	USD	Annual
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$10.04M	USD	Annual
Sale of common shares, including at-the-market transactions	`StockIssuedDuringPeriodValueSaleOfCommonSharesIncludingAtthemarketTransactions`	$77.99M	USD	Annual
Financing costs paid to issue common shares, including at-the-market transactions	`StockIssuedDuringPeriodValueOther`	$-3.06M	USD	Annual
Stock options exercised	`StockIssuedDuringPeriodValueStockOptionsExercised`	$2.58M	USD	Annual
Warrants exercised	`StockIssuedDuringPeriodValueWarrantsExercised`	$2.63M	USD	Annual
Shares issued upon vesting of RSU, net of shares retired to pay employees taxes	`StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures`	-	USD	Annual
Shares issued upon vesting of RSU, net of shares retired to pay employees taxes	`StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures`	$-239.00K	USD	Annual
Issuance of common stock to Razor Genomics	`StockIssuedDuringPeriodValuePurchaseOfAssetsAsAPartOfBusinessAcquisition`	$5.76M	USD	Annual
Issuance of common stock to Chronix Biomedical	`StockIssuedDuringPeriodValueAcquisitions`	$3.30M	USD	Annual
Issuance of common shares, including at-the-market transactions, net of financing costs and underwriting discounts	`StockIssuedDuringPeriodValueIssuanceOfCommonSharesIncludingAtthemarketTransactionsNetOfFinancingCostsAndUnderwritingDiscounts`	$32.45M	USD	Annual
Issuance of Series A redeemable convertible preferred stock, net of financing costs	`StockIssuedDuringPeriodValueConversionOfUnits`	-	USD	Annual
Accretion of Series A convertible preferred stock to redemption value	`StockIssuedDuringPeriodValueAccretionOfSeriesConvertiblePreferredStockToRedemptionValue`	$-520.00K	USD	Annual
Balance	`StockholdersEquity`	$34.29M	USD	Point-in-time
Balance	`StockholdersEquity`	$65.22M	USD	Point-in-time
Balance	`StockholdersEquity`	$33.48M	USD	Point-in-time

Comprehensive Income 6 line items

Line Item	Tag	Value	Unit	Period
NET LOSS	`NetIncomeLoss`	$-64.10M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-72.90M	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$37.00K	USD	Annual
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$2.00K	USD	Annual
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-64.06M	USD	Annual
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-72.90M	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.